Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SREBF2 | Q12772 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 2/20 | 0.35 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19640556 | 1.00 | SREBF2 (0.52) | SREBF2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL19640503 | 0.95 | SREBF2 (0.60) | SREBF2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL19640505 | 0.95 | SREBF2 (0.60) | SREBF2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL19640405 | 0.93 | SREBF2 (0.51) | SREBF2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL19640404 | 0.93 | SREBF2 (0.51) | SREBF2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL19640676 | 0.88 | SREBF2 (0.59) | SREBF2MAPTMEN1KMT2ARAB9A | |
| SCHEMBL19640673 | 0.88 | SREBF2 (0.59) | SREBF2MAPTMEN1KMT2ARAB9A | |
| SCHEMBL17790858 | 0.84 | SREBF2 (0.63) | SREBF2ALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL17785131 | 0.84 | SREBF2 (0.63) | SREBF2ALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL17785133 | 0.84 | SREBF2 (0.63) | SREBF2ALDH1A1MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170342046-A1 | Fatty Acid Cysteine-Based Conjugates and Their Use in Treating Medical Disorders | CATABASIS PHARMACEUTICALS, INC. | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342046-A1 | Fatty Acid Cysteine-Based Conjugates and Their Use in Treating Medical Disorders | CPT2, FABP1, ACAA2 | SREBF2 188/4885ALDH1A1 1220/4885MAPT 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.